IDEAYA Biosciences (IDYA) Corporate presentation summary

Vision and strategy

• Aims to be a leader in precision medicine oncology, focusing on first- and best-in-class programs using predictive biomarkers and AI-driven drug discovery.

• Pipeline targets rational combinations, neoadjuvant/adjuvant indications, and first-line metastatic disease.

Drug discovery platform

• Six internally discovered clinical-stage molecules across six potential first-in-class targets.

• Utilizes physics and AI-based drug design, CRISPR-based target discovery, and chemigenomic translational research.

• Achieved novel selectivity profiles against challenging target classes.

Clinical pipeline highlights

• Darovasertib targets uveal melanoma (UM), showing improved survival and eye preservation.

• IDE849 (DLL3 ADC) and IDE161 (PARG inhibitor) are being developed for solid tumors, with promising efficacy in SCLC and NEC.

• MTAP pathway programs (IDE397, IDE892) exploit synthetic lethality in ~15% of solid tumors.

• IDE034 (B7H3/PTK7 bispecific ADC) and IDE574 (KAT6/7 inhibitor) address tumor heterogeneity and resistance.